ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 208

Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)

Patricia Katz1, Sofia Pedro 2 and Kaleb Michaud 3, 1University of California, San Francisco, san francisco, CA, 2FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 3FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Rheumatoid arthritis (RA), sleep, sleep disorders and sleep apnea

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Epidemiology & Public Health Poster I: RA – ARP

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Sleep disturbances (SD) are reported to be common in RA but relatively few studies have addressed the issue. We examined the frequency and severity of self-reported poor sleep quality, symptoms of restless leg syndrome (RLS), and risk of obstructive sleep apnea (OSA) among individuals with RA, and identified predictors of SD.

Methods: Data were from FORWARD, the National Data Bank for Rheumatic Diseases, for which participants complete questionnaires every 6 months.  In one questionnaire, items querying symptoms of RLS, the STOP-BANG questionnaire, a validated measure of OSA risk, physician diagnoses of OSA and RLS, and the Medical Outcomes Study Sleep Scale (MOS-S) were included. The MOS-S yields 5 subscales; results are shown here only for one (Sleep Problems Index I, SPI-I, sleep quality). was also included.  Frequencies of reports of OSA risk, RLS symptoms were tabulated. Bivariate regression analyses identified predictors of OSA and RLS (logistic regression) and SPI-I scores (linear regression).  Potential predictors included age, sex, race, education, smoking, Rheumatic Disease Comorbidity Index (RDCI)1, low income, obesity (BMI ≥ 30 kg/m2 and < 35), morbid obesity (BMI ≥ 35), RA duration, prednisone and other medication use, and RA disease activity (Rheumatoid Arthritis Disease Activity Index, RADAI).  Variables significant in the bivariate analyses were included in multivariate regression analyses.

Results: Subject characteristics are shown in Table 1 (n = 2623).  16% reported physician-diagnosed OSA, and 14% were at high risk of OSA based on self-reported symptoms (Table 2), compared to 2-4% in the general population.  Only half at high risk had an OSA diagnosis.  12% reported physician-diagnosed RLS, and 26% reported RLS symptoms, compared to ~10% in the general population.  Only one third with RLS symptoms reported a physician diagnosis.  Mean SPI-I was 33.4 (±18.9), ~0.5 standard deviation worse than a population sample mean. Independent predictors of high risk of OSA were male sex, obesity, current smoking, RDCI, and disease activity (Table 3). Predictors of RLS symptoms were morbid obesity and disease activity.  Worse scores on SPI-I were associated with younger age, female sex, smoking, higher RDCI, shorter RA duration, and greater disease activity.  OSA and RLS symptoms were also independently associated with SPI-I scores.

Conclusion: Symptoms of both OSA and RLS were more common in RA than in the population; self-reported sleep quality was also worse.  Some predictors of SDs were similar to predictors in the population (e.g., age, obesity), but disease activity was also consistently associated with SD.  Research in RA has linked SDs to worse outcomes. Previous research in other conditions suggests that SDs might also be a cause of increased disease activity through heighted inflammation.  Further research is needed to tease out disease-specific causes and effects of SD in RA.

1 England BR et al. Arthritis Care Res 2015; 6: 865

2 Hays RD et al.  Sleep Med 2005; 6:41

3 Chung F et al. J Clin Sleep Med 2014; 10:951


Sleep disturbances in RA table 1


Sleep disturbances in RA table 2


Sleep disturbances in RA table 3


Disclosure: P. Katz, None; S. Pedro, FORWARD, the National Data Bank for Rheumatic Disease, 3, FORWARD, The National Data Bank for Rheumatic Diseases, 3; K. Michaud, Pfizer, 2, Rheumatology Research Foundation, 2.

To cite this abstract in AMA style:

Katz P, Pedro S, Michaud K. Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/self-reported-sleep-disturbances-in-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/self-reported-sleep-disturbances-in-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology